For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

Purpose: Patients with acute myeloid leukemia (AML) frequently do not respond to
conventional therapies. Leukemic cell survival and treatment resistance have been …

Apoptosis is an evolutionarily conserved sequential process of cell death to maintain a
homeostatic balance between cell formation and cell death. It is a vital process for normal …

Despite the remarkable success of chimeric antigen receptor (CAR) T-cell therapy for
treating hematologic malignancies, resistance and recurrence still occur, while the markers …

Innate and acquired resistance towards the conventional therapeutic regimen imposes a
significant challenge for the successful management of cancer for decades. In patients with …

The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients
exhibiting the 11; 14 translocation, the mechanistic basis of which is unknown. In evaluating …

The ability to inhibit mitochondrial apoptosis is a hallmark of B-cell non-Hodgkin lymphomas
(B-NHL). Activation of mitochondrial apoptosis is tightly controlled by members of B-cell …

The remarkable genetic heterogeneity of multiple myeloma poses a substantial challenge
for proper prognostication and clinical management of patients. Here, we introduce MM …

The development of resistance to anti-cancer therapeutics remains one of the core issues
preventing the improvement of survival rates in cancer. Therapy resistance can arise in a …